Methods and materials for treating human papillomavirus infections
The invention provides methods and materials related to treating HPV infections (e.g., HPV infections of cutaneous and mucosal epithelial cells) and HPV-associated conditions (e.g., cervical dysplasia, HPV-associated cervical carcinomas, oral mucosal papilloma cancers, laryngeal papilloma cancers).
1. A method of treating HPV infection comprising administering an effective amount of a nucleic acid molecule to a patient in need thereof, wherein said nucleic acid molecule inhibits expression associated with HPV replication, wherein said nucleic acid molecule comprises double-stranded RNA or encodes a nucleic acid comprising double-stranded RNA, and wherein at least one strand of said double-stranded RNA comprises a sequence that is complementary to nucleotides 129 to 147 of SEQ ID NO:85.
2. The method of claim 1 , wherein said nucleic acid molecule is administered topically.
3. The method of claim 2 , wherein said nucleic acid molecule is administered topically to a portion of the genital organ of said patient.
4. The method of claim 2 , wherein said nucleic acid molecule is administered topically to cervical tissue of said patient.
5. The method of claim 1 , wherein said patient suffers from cervical intraepithelial dysplasia (CIN).
6. The method of claim 5 , wherein said CIN is CIN I or mild dysplasia.
7. The method of claim 5 , wherein said CIN is CIN II or moderate to marked dysplasia.
8. The method of claim 5 , wherein said CIN is CIN III or severe dysplasia to carcinoma-in-situ.
9. The method of claim 8 , wherein said carcinoma-in-situ is localized to the intraepithelial tissue or the superficial layer of the cervix.
10. A method for treating a mammal having cells infected with HPV, said method comprising administering a nucleic acid molecule to said mammal under conditions wherein the number of said cells infected with said HPV is reduced, wherein said nucleic acid molecule comprises a sequence complementary to nucleotides 129 to 147 of SEQ ID NO:85, wherein said nucleic acid comprises double-stranded RNA molecule or encodes a nucleic acid comprising double-stranded RNA.
11. The method of claim 10 , wherein said mammal is a non-human, immunodeficient mammal, and wherein said cells are human cells.
12. The method of claim 10 , wherein said mammal is a nude or SCID mouse.
13. The method of claim 10 , wherein said mammal is a human.
14. The method of claim 10 , wherein said cell is a skin cell or epithelial cell.
15. The method of claim 10 , wherein said nucleic acid molecule is administered topically to said mammal.
16. The method of claim 15 , wherein said nucleic acid molecule is administered topically to a portion of the genital organ of said mammal.
17. The method of claim 15 , wherein said nucleic acid molecule is administered topically to cervical tissue of said mammal.
18. The method of claim 10 , wherein the number of said cells infected with said HPV is reduced by at least 25 percent.
19. The method of claim 10 , wherein the number of said cells infected with said HPV is reduced by at least 50 percent.
20. The method of claim 10 , wherein the number of said cells infected with said HPV is reduced by at least 75 percent.
21. The method of claim 10 , wherein said cells infected with said HPV contain non-integrated HPV nucleic acid.
22. The method of claim 10 , wherein said cells infected with said HPV contain replicating HPV.